Lipid changes after switch from tenofovir disoproxil fumarate to tenofovir alafenamide: a longitudinal cohort study

被引：0
|
作者：
Berger, F. [1 ]
Milinkovic, A. [2 ]
Arenas-Pinto, A. [3 ]
Mauss, S. [1 ]
机构：
[1] Ctr HIV & Hepatogastroenterol, HIV & Hepatogastroenterol, Dusseldorf, Germany
[2] Chelsea & Westminster Hosp, Dept HIV Med, London, England
[3] UCL, Inst Global Hlth, London, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P195
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2
    Cusato, Jessica
    Calcagno, Andrea
    De Nicolo, Amedeo
    Mogyorosi, Karoly
    D'Avolio, Antonio
    Di Perri, Giovanni
    Bonora, Stefano
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019, 94 (02) : 202 - 204
  • [42] Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study
    Moschopoulos, Charalampos D.
    Protopapas, Konstantinos
    Thomas, Konstantinos
    Kavatha, Dimitra
    Papadopoulos, Antonios
    Antoniadou, Anastasia
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2023, 39 (02) : 68 - 75
  • [43] Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
    Hill, Andrew
    Hughes, Sophie L.
    Gotham, Dzintars
    Pozniak, Anton L.
    JOURNAL OF VIRUS ERADICATION, 2018, 4 (02) : 72 - 79
  • [44] Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults living with HIV: a multicentre prospective cohort study
    Martinez-Sanz, J.
    Serrano-Villar, S.
    Muriel, A.
    Garcia Fraile, L.
    Orviz, E.
    Mena de Cea, A.
    Campins, A.
    Moreno Guillen, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 140 - 141
  • [45] Switch from tenofovir disoproxil fumarate (TDF)- to tenofovir alafenamide (TAF)-based regimens in clinical practice: real-world data of the German PROPHET cohort study
    Bickel, M.
    Wyen, C.
    Spinner, C.
    Baumgarten, A.
    Jaeger, H.
    Postel, N.
    Wolf, E.
    Hoffmann, C.
    Esser, S.
    Klauke, S.
    Schewe, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [46] Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
    Seo, Jun-Won
    Kim, Kichun
    Jun, Kang Il
    Kang, Chang Kyung
    Moon, Song Mi
    Song, Kyoung-Ho
    Bang, Ji-Hwan
    Kim, Eu Suk
    Kim, Hong Bin
    Park, Sang Won
    Kim, Nam Joong
    Choe, Pyoeng Gyun
    Park, Wan Beom
    Oh, Myoung-don
    INFECTION AND CHEMOTHERAPY, 2020, 52 (03): : 381 - 388
  • [47] Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
    Lin, Shenglong
    Huang, Wanlong
    Liao, Ziyuan
    Ma, Huaxi
    Wu, Wenjun
    Lin, Minghua
    Huang, Defu
    Gao, Haibing
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [48] The Comparison of tenofovir alafenamide fumarate with tenofovir disoproxil fumarate in preventing hepatitis B transmission in mothers with high viral load: a retrospective cohort study
    Zhu, Yunxia
    Wang, Jinhua
    Wang, Ming
    Zhou, Xin
    Zhang, Shuangxia
    Zhang, Shujie
    Yang, Bo
    Yang, Ping
    Hu, Zhongjie
    JOURNAL OF HEPATOLOGY, 2022, 77 : S272 - S272
  • [49] COMPARATIVE SAFETY OF TENOFOVIR DISOPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS
    Yu, N. Y.
    Chang, K. C.
    VALUE IN HEALTH, 2020, 23 : S532 - S532
  • [50] Tenofovir alafenamide compared to tenofovir disoproxil fumarate, induces dysglycemia, and dyslipidemia in Wistar rats
    Hurchund, Rajendraparsad
    Sibiya, Sinegugu E.
    Owaga, Bernard O.
    Owira, Peter M. O.
    AIDS, 2024, 38 (13) : 1809 - 1818
12345